KTE-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study From the DESCAR-T Registry and LYSA Group

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [31] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results from Phase 2 of ZUMA-2
    Wang, Michael
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    MOLECULAR THERAPY, 2020, 28 (04) : 573 - 573
  • [32] Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
    Wang, Michael
    Rossi, John M.
    Munoz, Javier
    Goy, Andre
    Locke, Frederick Lundry
    Reagan, Patrick Michael
    Jacobson, Caron A.
    Hill, Brian T.
    Holmes, Houston
    Jaglowski, Samantha Mary
    Peng, Weimin
    Zheng, Lianqing
    Fang, Xiang
    Xue, Allen
    Rao, Arati, V
    Bot, Adrian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] EFFICACY AND SAFETY OF IBRUTINIB THERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN REAL-LIFE A MULTICENTRIC STUDY (REP - APULIAN HEMATOLOGY NETWORK)
    Gagliardi, V. P.
    Cascavilla, N.
    Di Renzo, N.
    Melpignano, A.
    Loseto, G.
    Pavone, V.
    Gaudio, F.
    Specchia, G.
    Perrone, T.
    HAEMATOLOGICA, 2017, 102 : 693 - 693
  • [34] Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
    Lemoine, Jean
    Bachy, Emmanuel
    Cartron, Guillaume
    Beauvais, David
    Gastinne, Thomas
    Rubio, Marie Therese
    Leleu, Xavier
    Mohty, Mohamad
    Casasnovas, Rene-Olivier
    Joris, Magalie
    Castilla-LLorente, Cristina
    Haioun, Corinne
    Hermine, Olivier
    Loschi, Michael
    Carras, Sylvain
    Bories, Pierre
    Fradon, Tom
    Herbaux, Charles
    Sesques, Pierre
    Le Gouill, Steven
    Morschhauser, Franck
    Thieblemont, Catherine
    Houot, Roch
    BLOOD, 2022, 140 : 1859 - 1861
  • [35] French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry
    Ferment, B.
    Lambert, J.
    Caillot, D.
    Lafon, I.
    Karlin, L.
    Lazareth, A.
    Touzeau, C.
    Leleu, X.
    Moya, N.
    Harel, S.
    Perrot, A.
    Bories, P.
    Vincent, L.
    Lamure, S.
    Mohty, M.
    Malard, F.
    Manier, S.
    Yakoub-Agha, I.
    Schiano De Colella, J. -m.
    Brisou, G.
    Talbot, A.
    Decaux, O.
    Houot, R.
    Le Gouill, S.
    Bigot, N.
    Facon, T.
    Corre, J.
    Moreau, P.
    Arnulf, B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 990 - 998
  • [36] Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry
    Gower, Nicolas
    Pizot, Cecile
    Dourthe, Marie-Emilie
    Gastinne, Thomas
    Brisou, Gabriel
    Guidez, Stephanie
    Tudesq, Jean-Jacques
    Chauchet, Adrien
    Herbreteau, Laura
    Campidelli, Arnaud
    Sesques, Pierre
    Chiche, Edmond
    Gros, Francois Xavier
    Durand, Amandine
    Lubnau, Marion
    Sterin, Arthur
    Di Blasi, Roberta
    Bay, Jacques-Olivier
    Marquet, Alexandra
    Gat, Elodie
    Houot, Roch
    Morschhauser, Franck
    Paillassa, Jerome
    BLOOD, 2024, 144 : 528 - 529
  • [37] Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa
    Ysebaert, Loic
    Houot, Roch
    Casasnovas, Olivier
    Sylvain, Choquet
    Jardin, Fabrice
    Loschi, Michael
    Brisou, Gabriel
    Thieblemont, Catherine
    Bay, Jacques-Olivier
    Castilla-Llorente, Cristina
    Fradon, Tom
    Le Gouill, Steven
    Morschhauser, Franck
    Cartron, Guillaume
    Bachy, Emmanuel
    BLOOD, 2023, 142
  • [38] Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study
    Shimony, Shai
    Horowitz, Netanel
    Ribakovsky, Elena
    Rozovski, Uri
    Avigdor, Abraham
    Zloto, Keren
    Berger, Tamar
    Avivi, Irit
    Perry, Chava
    Abadi, Uri
    Raanani, Pia
    Gafter-Gvili, Anat
    Gurion, Ronit
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (05) : 569 - 577
  • [39] Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group
    Regny, Caroline
    Malak, Sandra
    Manson, Guillaume
    Sarkozy, Clementine
    Clavert, Aline
    Herbaux, Charles
    Chauchet, Adrien
    Jourdan, Eric
    Sanhes, Laurence
    Godmer, Pascal
    Pascal, Laurent
    Le Du, Katell
    Sutton, Laurent
    Voillat, Laurent
    Dupuis, Jehan
    Anglaret, Bruno
    Gressin, Remy
    BLOOD, 2016, 128 (22)
  • [40] Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
    Baggio, Diva
    Wellard, Cameron
    Chung, Eliza
    Talaulikar, Dipti
    Keane, Colm
    Opat, Stephen
    Giri, Pratyush
    Minson, Adrian
    Cheah, Chan Yoon
    Armytage, Tasman
    Lee, Denise
    Chong, Geoffrey
    Johnston, Anna
    Cochrane, Tara
    Waters, Neil
    Hamad, Nada
    Wood, Erica M.
    Hawkes, Eliza A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 621 - 627
12345